<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643550</url>
  </required_header>
  <id_info>
    <org_study_id>IPH2201-203</org_study_id>
    <nct_id>NCT02643550</nct_id>
  </id_info>
  <brief_title>Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</brief_title>
  <official_title>Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Innate Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses
      of Monalizumab given IV in combination with cetuximab in patients who have received prior
      systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and
      neck (SCCHN).

      Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or
      without anti-PD(L)1
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Dose Limiting Toxicities (DLT) in the dose escalation part of the study</measure>
    <time_frame>within 4 weeks after first administration</time_frame>
    <description>To assess the occurrence of Drug Limited Toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate for expansion cohorts</measure>
    <time_frame>up to 12 months</time_frame>
    <description>rate of patients in complete or partial response according to RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate for dose escalation part of the study</measure>
    <time_frame>up to 12 months</time_frame>
    <description>rate of patients in complete or partial response according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for expansion cohorts</measure>
    <time_frame>From confirmed response until disease progression, up to 12 months</time_frame>
    <description>Duration of complete and partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival for expansion cohorts</measure>
    <time_frame>Until disease progression or death, up to 2 years</time_frame>
    <description>time between the start of treatment and the first documented progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival for expansion cohorts</measure>
    <time_frame>Until death, up to 2 years</time_frame>
    <description>time between the start of treatment and death</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of monalizumab in combination with cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monalizumab + cetuximab expansion cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monalizumab + cetuximab + anti-PD(L)1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monalizumab</intervention_name>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Expansion cohort 1</arm_group_label>
    <arm_group_label>Expansion cohort 2</arm_group_label>
    <arm_group_label>Expansion cohort 3</arm_group_label>
    <other_name>IPH2201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_label>Expansion cohort 1</arm_group_label>
    <arm_group_label>Expansion cohort 2</arm_group_label>
    <arm_group_label>Expansion cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-PD(L)1</intervention_name>
    <arm_group_label>Expansion cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Age ≥ 18 years

          2. Histologically or cytologically-confirmed, HPV (+) or HPV (-) squamous cell carcinoma
             of the nasopharynx (WHO Type 1), oropharynx, hypopharynx, larynx (supraglottis,
             glottis, subglottis) or oral cavity,

          3. Recurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or
             physical examination with measurable disease as per Response Evaluation Criteria in
             Solid Tumors [RECIST] 1.1

        For phase II cohorts:

          -  Cohort #1: Patients who received a maximum of two prior systemic regimens for
             recurrent and/or metastatic disease and not amenable to further therapy with curative
             intent

          -  Cohort #2: Patients with R/M SCCHN not amenable to therapy of curative intent,who have
             received a maximum of two prior systemic regimens in the R/M setting and who have
             received prior PD-(L)1 blockers

          -  Cohort #3: Patients with R/M SCCHN who have not received prior systemic regimens in
             the R/M setting and who have not received prior PD-(L)1 inhibitors

        Main Exclusion Criteria:

          1. For phase II cohort #1 and cohort #2: Patients who received more than 2 prior systemic
             regimens for recurrent and/or metastatic disease (no restriction in the phase Ib part
             of the trial).

          2. For phase II cohort #1 and cohort #2 : Patients who received cetuximab or another
             inhibitor of epidermal growth factor receptor are excluded from the phase II of the
             trial, except if cetuximab was given as part of a primary treatment approach, with no
             progressive disease for at least 4 months following the end of prior cetuximab
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agnes Boyer Chammard, MD</last_name>
    <phone>+33430303120</phone>
    <email>Agnes.BOYER-CHAMMARD@innate-pharma.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Franceline Calmels</last_name>
    <phone>+33430303062</phone>
    <email>Franceline.CALMELS@innate-pharma.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Colevas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>university of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanguy Lim-Seiwert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinaï</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall Posner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Cohen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Bauman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Bernadach, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gautier Lefebvre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Fayette, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Salas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Cupissol, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esma Saada Bouzid, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Vauleon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Rene Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Rolland, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Even, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

